34166 Federal Register / Vol. 87, No. 108 / Monday, June 6, 2022 / Rules and Regulations 

1As discussed in a memorandum of 

understanding entered into by the Food and Drug 

Administration (FDA) and the National Institute on 

Drug Abuse (NIDA), FDA acts as the lead agency 

within HHS in carrying out the Secretary’s 

scheduling responsibilities under the Controlled 

Substances Act, with the concurrence of NIDA. 50 

FR 9518 (March 8, 1985). The Secretary of HHS has 

delegated to the Assistant Secretary for Health of 

HHS the authority to make domestic drug 

scheduling recommendations. 58 FR 35460 (July 1, 

1993). 

2 21 U.S.C. 811(d)(3). 

thus avoid automatic classification in 

class III, it would have to comply with 

the special controls named in this final 

order. The necessary special controls 

appear in the regulation codified by this 

order. This device is subject to 

premarket notification requirements 

under section 510(k) of the FD&C Act. 

III. Analysis of Environmental Impact 

The Agency has determined under 21 

CFR 25.34(b) that this action is of a type 

that does not individually or 

cumulatively have a significant effect on 

the human environment. Therefore, 

neither an environmental assessment 

nor an environmental impact statement 

is required. 

IV. Paperwork Reduction Act of 1995 

This final order establishes special 

controls that refer to previously 

approved collections of information 

found in other FDA regulations and 

guidance. These collections of 

information are subject to review by the 

Office of Management and Budget 

(OMB) under the Paperwork Reduction 

Act of 1995 (44 U.S.C. 3501–3521). The 

collections of information in 21 CFR 

part 860, subpart D, regarding De Novo 

classification have been approved under 

OMB control number 0910–0844; the 

collections of information in 21 CFR 

part 814, subparts A through E, 

regarding premarket approval, have 

been approved under OMB control 

number 0910–0231; the collections of 

information in part 807, subpart E, 

regarding premarket notification 

submissions, have been approved under 

OMB control number 0910–0120; the 

collections of information in 21 CFR 

part 820, regarding quality system 

regulation, have been approved under 

OMB control number 0910–0073; and 

the collections of information in 21 CFR 

part 801, regarding labeling, have been 

approved under OMB control number 

0910–0485. 

List of Subjects in 21 CFR Part 876 

Medical devices. 

Therefore, under the Federal Food, 

Drug, and Cosmetic Act and under 

authority delegated to the Commissioner 

of Food and Drugs, 21 CFR part 876 is 

amended as follows: 

PART 876—GASTROENTEROLOGY– 

UROLOGY DEVICES 

■ 1. The authority citation for part 876 

continues to read as follows: 

Authority: 21 U.S.C. 351, 360, 360c, 360e, 

360j, 360l, 371. 

■ 2. Add § 876.5026 to subpart F to read 

as follows: 

§ 876.5026 Non-implanted electrical 

stimulation device for management of 

premature ejaculation. 

(a) Identification. A non-implanted 

electrical stimulation device for 

management of premature ejaculation is 

intended to be used in patients with 

premature ejaculation by delivery of 

electrical stimulation to the perineal 

muscles and nerves. 

(b) Classification. Class II (special 

controls). The special controls for this 

device are: 

(1) The device must be demonstrated 

to be biocompatible. 

(2) Performance testing must 

demonstrate the electromagnetic 

compatibility, electrical safety, and 

thermal safety of the device. 

(3) Non-clinical performance testing 

must demonstrate that the device 

performs as intended under anticipated 

conditions of use. The following 

performance characteristics must be 

tested: 

(i) Mechanical performance; 

(ii) Electrical stimulation parameters; 

and 

(iii) Battery performance. 

(4) Performance testing must support 

shelf life by demonstrating continued 

device functionality over the identified 

shelf life. 

(5) Software verification, validation, 

and hazard analysis must be performed. 

(6) Labeling must include: 

(i) Specific instructions regarding safe 

placement and correct use of the device; 

(ii) Warning(s) against use by patients 

with active implanted medical devices; 

and 

(iii) A shelf life. 

Dated: May 26, 2022. 

Lauren K. Roth, 

Associate Commissioner for Policy. 

[FR Doc. 2022–12082 Filed 6–3–22; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

21 CFR Part 1308 

[Docket No. DEA–568] 

Schedules of Controlled Substances: 

Placement of Methoxetamine (MXE) in 

Schedule I 

AGENCY: Drug Enforcement 

Administration, Department of Justice. 

ACTION: Final rule. 

SUMMARY: With the issuance of this final 

rule, the Drug Enforcement 

Administration places 2-(ethylamino)-2- 

(3-methoxyphenyl)cyclohexan-1-one 

(methoxetamine, MXE), including its 

salts, isomers, and salts of isomers 

whenever the existence of such salts, 

isomers, and salts of isomers is possible 

within the specific chemical 

designation, in schedule I of the 

Controlled Substances Act to enable the 

United States to meet its obligations 

under the 1971 Convention on 

Psychotropic Substances. This action 

imposes the regulatory controls and 

administrative, civil, and criminal 

sanctions applicable to schedule I 

controlled substances on persons who 

handle (manufacture, distribute, reverse 

distribute, import, export, engage in 

research, conduct instructional 

activities or chemical analysis with, or 

possess), or propose to handle, 

methoxetamine. 

DATES: Effective July 6, 2022. 

FOR FURTHER INFORMATION CONTACT: 

Terrence L. Boos, Drug & Chemical 

Evaluation Section, Diversion Control 

Division, Drug Enforcement 

Administration; Telephone: (571) 362– 

3249. 

SUPPLEMENTARY INFORMATION: 

Legal Authority 

The United States is a party to the 

1971 United Nations Convention on 

Psychotropic Substances (1971 

Convention), February 21, 1971, 32 

U.S.T. 543, 1019 U.N.T.S. 175, as 

amended. Procedures respecting 

changes in drug schedules under the 

1971 Convention are governed 

domestically by 21 U.S.C. 811(d)(2)–(4). 

When the United States receives 

notification of a scheduling decision 

pursuant to Article 2 of the 1971 

Convention indicating that a drug or 

other substance has been added to a 

specific schedule, the Secretary of the 

Department Health and Human Services 

(HHS),1 after consultation with the 

Attorney General, shall determine 

whether existing legal controls under 

subchapter I of the Controlled 

Substances Act (CSA) and the Federal 

Food, Drug, and Cosmetic Act meet the 

requirements of the schedule specified 

in the notification with respect to the 

specific drug or substance.2 In the event 

that the Secretary of HHS did not 

consult with the Attorney General, and 


lotter on DSK11XQN23PROD with RULES1
Federal Register / Vol. 87, No. 108 / Monday, June 6, 2022 / Rules and Regulations 34167 

3 28 CFR 0.100. 

4Although there is no evidence suggesting that 

methoxetamine has a currently accepted medical 

use in treatment in the United States, it bears noting 

that a drug cannot be found to have such medical 

use unless DEA concludes that it satisfies a five-part 

test. Specifically, with respect to a drug that has not 

been approved by FDA, to have a currently 

accepted medical use in treatment in the United 

States, all of the following must be demonstrated: 

i. The drug’s chemistry must be known and 

reproducible; ii. there must be adequate safety 

studies; iii. there must be adequate and wellcontrolled studies proving efficacy; iv. the drug 

must be accepted by qualified experts; and v. the 

scientific evidence must be widely available. 57 FR 

10499 (1992), pet. for rev. denied, Alliance for 

Cannabis Therapeutics v. DEA, 15 F.3d 1131, 1135 

(D.C. Cir. 1994). 

5 21 U.S.C. 812(b)(1). 

the Attorney General did not issue a 

temporary order, as provided under 21 

U.S.C. 811(d)(4), the procedures for 

permanent scheduling set forth in 21 

U.S.C. 811(a) and (b) control. Pursuant 

to 21 U.S.C. 811(a)(1), the Attorney 

General may, by rule, schedule or 

transfer between any schedules any 

drug or other substance, if he finds that 

such drug or other substance has a 

potential for abuse, and makes the 

findings prescribed by 21 U.S.C. 812(b) 

to schedule the drug or other substance. 

The Attorney General has delegated this 

scheduling authority to the 

Administrator of the Drug Enforcement 

Administration (DEA).3

Background 

Methoxetamine, also known as 2- 

(ethylamino)-2-(3- 

methoxyphenyl)cyclohexan-1-one or 2- 

(3-methoxyphenyl)-2-(Nethylamino)cyclohexanone or MXE, 

belongs to the arylcyclohexylamine 

class of drugs with dissociative 

anesthetic and hallucinogenic 

properties, similar to phencyclidine 

(PCP), a schedule II controlled 

substance, and ketamine, a schedule III 

controlled substance. Methoxetamine 

has no approved medical use in the 

United States. In March 2016, the 

Commission on Narcotic Drugs (CND) 

voted to place methoxetamine in 

Schedule II of the 1971 Convention 

(CND Dec/59/6) during its 59th Session 

due to its dependence and abuse 

potential. 

DEA and HHS Eight Factor Analyses 

On April 14, 2018, in accordance with 

21 U.S.C. 811(b), and in response to 

DEA’s December 30, 2014, request and 

April 14, 2017, submission of additional 

data, HHS provided to DEA a scientific 

and medical evaluation and scheduling 

recommendation for methoxetamine. 

DEA reviewed the scientific and 

medical evaluation and scheduling 

recommendation for schedule I 

placement provided by HHS, and all 

other relevant data, pursuant to 21 

U.S.C. 811(b) and (c), and conducted its 

own analysis under the eight factors 

stipulated in 21 U.S.C. 811(c). DEA 

found, under 21 U.S.C. 811(b)(1), that 

this substance warrants control in 

schedule I. Both DEA and HHS EightFactor analyses are available in their 

entirety under the tab Supporting 

Documents of the public docket for this 

action at https://www.regulations.gov 

under docket number DEA–568. 

Notice of Proposed Rulemaking To 

Schedule Methoxetamine 

On December 7, 2021 (86 FR 69187), 

DEA published a notice of proposed 

rulemaking (NPRM) to permanently 

control methoxetamine in schedule I. 

Specifically, DEA proposed to add 

methoxetamine to the hallucinogenic 

substances list under 21 CFR 

1308.11(d). The NPRM provided an 

opportunity for interested persons to file 

a request for hearing in accordance with 

DEA regulations on or before February 

7, 2022. No requests for such a hearing 

were received by DEA. The NPRM also 

provided an opportunity for interested 

persons to submit comments on or 

before February 7, 2022. 

Comments Received 

DEA received one comment that 

recognized the dangers and public 

health risks, and fully supported the 

placement of methoxetamine in 

schedule I. 

DEA Response: DEA appreciates this 

comment in support of this rulemaking. 

Scheduling Conclusion 

After consideration of the public 

comment, scientific and medical 

evaluation and accompanying 

recommendation of HHS, and after its 

own eight-factor evaluation, DEA finds 

that these facts and all relevant data 

constitute substantial evidence of 

potential for abuse of methoxetamine. 

DEA is permanently scheduling 

methoxetamine as a controlled 

substance under the CSA. 

Determination of Appropriate Schedule 

The CSA establishes five schedules of 

controlled substances known as 

schedules I, II, III, IV, and V. The CSA 

also specifies the findings required to 

place a drug or other substance in any 

particular schedule, 21 U.S.C. 812(b). 

After consideration of the analysis and 

recommendation of the Acting Assistant 

Secretary for Health of HHS and review 

of all other available data, the 

Administrator of DEA, pursuant to 21 

U.S.C. 812(b)(1), finds that: 

(1) Methoxetamine has a high 

potential for abuse that is comparable to 

other scheduled substances such as the 

ethylamine analog of phencyclidine 

(PCE; schedule I), the thiophene analog 

of phencyclidine (TCP; schedule I), 

phencyclidine (PCP; schedule II), and 

ketamine (schedule III); 

(2) Methoxetamine has no currently 

accepted medical use in treatment in the 

United States. There are no approved 

New Drug Applications for 

methoxetamine and no known 

therapeutic applications for 

methoxetamine in the United States. 

Therefore, methoxetamine has no 

currently accepted medical use in 

treatment in the United States.4

(3) There is a lack of accepted safety 

for use of methoxetamine under medical 

supervision. Because methoxetamine 

has no approved medical use and has 

not been investigated as a new drug, its 

safety for use under medical supervision 

has not been determined. Therefore, 

there is a lack of accepted safety for use 

of methoxetamine under medical 

supervision. 

Based on these findings, the 

Administrator of DEA concludes that 

methoxetamine as well as its salts, 

isomers, and salts of isomers whenever 

the existence of such salts, isomers, and 

salts of isomers is possible warrants 

control in schedule I of the CSA.5

Requirements for Handling 

Methoxetamine 

Methoxetamine is subject to the CSA’s 

schedule I regulatory controls and 

administrative, civil, and criminal 

sanctions applicable to the manufacture, 

distribution, reverse distribution, 

import, export, engagement in research, 

conduct instructional activities or 

chemical analysis with, and possession 

of schedule I controlled substances, 

including the following: 

1. Registration. Any person who 

handles (manufactures, distributes, 

reverse distributes, imports, exports, 

engages in research, or conducts 

instructional activities or chemical 

analysis with, or possesses), or who 

desires to handle, methoxetamine must 

be registered with DEA to conduct such 

activities pursuant to 21 U.S.C. 822, 

823, 957, and 958, and in accordance 

with 21 CFR parts 1301 and 1312. Any 

person who currently handles 

methoxetamine and is not registered 

with DEA must submit an application 

for registration and may not continue to 

handle methoxetamine, unless DEA has 

approved that application for 

registration pursuant to 21 U.S.C. 822, 

823, 957, 958, and in accordance with 

21 CFR parts 1301 and 1312. 


lotter on DSK11XQN23PROD with RULES1
34168 Federal Register / Vol. 87, No. 108 / Monday, June 6, 2022 / Rules and Regulations 

6 44 U.S.C. 3501–3521. 

2. Disposal of stocks. Any person 

unwilling or unable to obtain a schedule 

I registration must surrender or transfer 

all quantities of currently held 

methoxetamine to a person registered 

with DEA before the effective date of a 

final scheduling action in accordance 

with all applicable Federal, State, local, 

and tribal laws. Methoxetamine must be 

disposed of in accordance with 21 CFR 

part 1317, in addition to all other 

applicable Federal, State, local, and 

tribal laws. 

3. Security. Methoxetamine is subject 

to schedule I security requirements and 

must be handled and stored pursuant to 

21 U.S.C. 823, and in accordance with 

21 CFR 1301.71–1301.76, as of the 

effective date of this final scheduling 

action. Non-practitioners handling 

methoxetamine must comply with the 

employee screening requirements of 21 

CFR 1301.90–1301.93. 

4. Labeling and Packaging. All labels, 

labeling, and packaging for commercial 

containers of methoxetamine must 

comply with 21 U.S.C. 825, and be in 

accordance with 21 CFR part 1302. 

5. Quota. Only registered 

manufacturers are permitted to 

manufacture methoxetamine in 

accordance with a quota assigned 

pursuant to 21 U.S.C. 826, and in 

accordance with 21 CFR part 1303. 

6. Inventory. Every DEA registrant 

who possesses any quantity of 

methoxetamine must take an inventory 

of methoxetamine on hand, pursuant to 

21 U.S.C. 827 and in accordance with 21 

CFR 1304.03, 1304.04, and 1304.11(a) 

and (d). 

Any person who registers with DEA 

must take an initial inventory of all 

stocks of controlled substances 

(including methoxetamine) on hand on 

the date the registrant first engages in 

the handling of controlled substances, 

pursuant to 21 U.S.C. 827 and in 

accordance with 21 CFR 1304.03, 

1304.04, and 1304.11(a) and (b). 

After the initial inventory, every DEA 

registrant must take an inventory of all 

controlled substances (including 

methoxetamine) on hand every two 

years, pursuant to 21 U.S.C. 827 and in 

accordance with 21 CFR 1304.03, 

1304.04, and 1304.11. 

7. Records and Reports. Every DEA 

registrant must maintain records and 

submit reports for methoxetamine, or 

products containing methoxetamine, 

pursuant to 21 U.S.C. 827 and in 

accordance with 21 CFR 1301.74(b) and 

(c) and parts 1304, 1312 and 1317. 

Manufacturers and distributors must 

submit reports regarding methoxetamine 

to the Automation of Reports and 

Consolidated Order System pursuant to 

21 U.S.C. 827 and in accordance with 21 

CFR parts 1304 and 1312. 

8. Order Forms. Every DEA registrant 

who distributes methoxetamine must 

comply with the order form 

requirements, pursuant to 21 U.S.C. 828 

and 21 CFR part 1305. 

9. Importation and Exportation. All 

importation and exportation of 

methoxetamine must comply with 21 

U.S.C. 952, 953, 957, and 958, and in 

accordance with 21 CFR part 1312. 

10. Liability. Any activity involving 

methoxetamine not authorized by, or in 

violation of, the CSA or its 

implementing regulations, is unlawful, 

and may subject the person to 

administrative, civil, and/or criminal 

sanctions. 

Regulatory Analyses 

Executive Orders 12866 and 13563 

(Regulatory Planning and Review; 

Improving Regulation and Regulatory 

Review) 

In accordance with 21 U.S.C. 811(a), 

this final scheduling action is subject to 

formal rulemaking procedures 

performed ‘‘on the record after 

opportunity for a hearing,’’ which are 

conducted pursuant to the provisions of 

5 U.S.C. 556 and 557. The CSA sets 

forth the procedures and criteria for 

scheduling a drug or other substance. 

Such actions are exempt from review by 

the Office of Management and Budget 

pursuant to section 3(d)(1) of Executive 

Order (E.O.) 12866 and the principles 

reaffirmed in E.O. 13563. 

Executive Order 12988, Civil Justice 

Reform 

This regulation meets the applicable 

standards set forth in sections 3(a) and 

3(b)(2) of E.O. 12988 to eliminate 

drafting errors and ambiguity, minimize 

litigation, provide a clear legal standard 

for affected conduct, and promote 

simplification and burden reduction. 

Executive Order 13132, Federalism 

This rulemaking does not have 

federalism implications warranting the 

application of E.O. 13132. The proposed 

rule does not have substantial direct 

effects on the States, on the relationship 

between the national government and 

the States, or on the distribution of 

power and responsibilities among the 

various levels of government. 

Executive Order 13175, Consultation 

and Coordination With Indian Tribal 

Governments 

This rule does not have tribal 

implications warranting the application 

of E.O. 13175. It does not have 

substantial direct effects on one or more 

Indian tribes, on the relationship 

between the Federal Government and 

Indian tribes, or on the distribution of 

power and responsibilities between the 

Federal Government and Indian tribes. 

Paperwork Reduction Act of 1995 

This action does not impose a new 

collection of information requirement 

under the Paperwork Reduction Act of 

1995.6

Regulatory Flexibility Act 

The Administrator of DEA, in 

accordance with the Regulatory 

Flexibility Act, 5 U.S.C. 601–612, has 

reviewed this final rule, and by 

approving it, certifies that it will not 

have a significant economic impact on 

a substantial number of small entities. 

DEA is placing the substance 

methoxetamine (chemical name: 2- 

(ethylamino)-2-(3- 

methoxyphenyl)cyclohexan-1-one)), 

including its salts, isomers, and salts of 

isomers whenever the existence of such 

salts, isomers, and salts of isomers is 

possible within the specific chemical 

designation, in schedule I of the CSA to 

enable the United States to meet its 

obligations under the 1971 Convention. 

This action imposes the regulatory 

controls and administrative, civil, and/ 

or criminal sanctions applicable to 

schedule I controlled substances on 

persons who handle (manufacture, 

distribute, reverse distribute, import, 

export, engage in research, conduct 

instructional activities or chemical 

analysis with, or possess) or propose to 

handle methoxetamine. 

Based on the review of HHS’s 

scientific and medical evaluation and 

all other relevant data, DEA determined 

that methoxetamine has high potential 

for abuse, has no currently accepted 

medical use in treatment in the United 

States, and lacks accepted safety for use 

under medical supervision. DEA’s 

research confirms that there is no 

legitimate commercial market for 

methoxetamine in the United States. 

Therefore, this final rule will not have 

a significant effect on a substantial 

number of small entities. 

Unfunded Mandates Reform Act of 1995 

On the basis of information contained 

in the ‘‘Regulatory Flexibility Act’’ 

section above, DEA has determined 

pursuant to the Unfunded Mandates 

Reform Act (UMRA) of 1995 (2 U.S.C. 

1501 et seq.) that this final rule would 

not result in any Federal mandate that 

may result ‘‘in the expenditure by State, 

local, and tribal governments, in the 

aggregate, or by the private sector, of 

$100,000,000 or more (adjusted 


lotter on DSK11XQN23PROD with RULES1
Federal Register / Vol. 87, No. 108 / Monday, June 6, 2022 / Rules and Regulations 34169 

annually for inflation) in any 1 year 

* * *.’’ Therefore, neither a Small 

Government Agency Plan nor any other 

action is required under UMRA of 1995. 

Congressional Review Act 

This rule is not a major rule as 

defined by the Congressional Review 

Act (CRA), 5 U.S.C. 804. However, 

pursuant to the CRA, DEA is submitting 

a copy of the final rule to both Houses 

of Congress and to the Comptroller 

General. 

List of Subjects in 21 CFR Part 1308 

Administrative practice and 

procedure, Drug traffic control, 

Reporting and recordkeeping 

requirements. 

For the reasons set out above, 21 CFR 

part 1308 is amended as follows: 

PART 1308—SCHEDULES OF 

CONTROLLED SUBSTANCES 

■ 1. The authority citation for 21 CFR 

part 1308 continues to read as follows: 

Authority: 21 U.S.C. 811, 812, 871(b), 

956(b), unless otherwise noted. 

■ 2. In § 1308.11, add paragraph (d)(100) 

to read as follows: 

§ 1308.11 Schedule I. 

* * * * * 

(d) * * * 

(100) 2-(ethylamino)-2-(3-methoxyphenyl)cyclohexan-1-one (methoxetamine, MXE) .................................................................................. 7286 

* * * * * 

Anne Milgram, 

Administrator. 

[FR Doc. 2022–11933 Filed 6–3–22; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF THE TREASURY 

Office of Foreign Assets Control 

31 CFR Part 587 

Publication of Russian Harmful 

Foreign Activities Sanctions 

Regulations Web General Licenses 

25A, 33, 34, and 35 

AGENCY: Office of Foreign Assets 

Control, Treasury. 

ACTION: Publication of Web General 

Licenses. 

SUMMARY: The Department of the 

Treasury’s Office of Foreign Assets 

Control (OFAC) is publishing four 

general licenses (GLs) issued pursuant 

to the Russian Harmful Foreign 

Activities Sanctions Regulations: GL 

25A, GL 33, GL 34, and GL 35, each of 

which was previously issued on OFAC’s 

website. 

DATES: GL 25A, GL 33, GL 34, and GL 

35 were each issued on May 8, 2022. 

See SUPPLEMENTARY INFORMATION of this 

publication for additional relevant 

dates. 

FOR FURTHER INFORMATION CONTACT: 

OFAC: Assistant Director for Licensing, 

202–622–2480; Assistant Director for 

Regulatory Affairs, 202–622–4855; or 

Assistant Director for Sanctions 

Compliance & Evaluation, 202–622– 

2490. 

SUPPLEMENTARY INFORMATION: 

Electronic Availability 

This document and additional 

information concerning OFAC are 

available on OFAC’s website: 

www.treas.gov/ofac. 

Background 

OFAC issued GL 25A, GL 33, GL 34, 

and GL 35 on May 8, 2022 on its website 

to authorize certain transactions 

otherwise prohibited by the Russian 

Harmful Foreign Activities Sanctions 

Regulations, 31 CFR part 587. GL 25A 

does not contain an expiration date. GL 

33 expires at 12:01 a.m. eastern daylight 

time, June 7, 2022. GL 34 expires at 

12:01 a.m. eastern daylight time, July 7, 

2022. GL 35 expires at 12:01 a.m. 

eastern daylight time, August 20, 2022. 

The texts of GLs 25A, 33, 34, and 35 are 

provided below. 

OFFICE OF FOREIGN ASSETS 

CONTROL 

Russian Harmful Foreign Activities 

Sanctions Regulations 31 CFR Part 587 

GENERAL LICENSE NO. 25A 

Authorizing Transactions Related to 

Telecommunications and Certain 

Internet-Based Communications 

(a) Except as provided in paragraph 

(c) of this general license, all 

transactions ordinarily incident and 

necessary to the receipt or transmission 

of telecommunications involving the 

Russian Federation that are prohibited 

by the Russian Harmful Foreign 

Activities Sanctions Regulations, 31 

CFR part 587 (RuHSR), are authorized. 

(b) Except as provided in paragraph 

(c) of this general license, the 

exportation or reexportation, sale, or 

supply, directly or indirectly, from the 

United States or by U.S. persons, 

wherever located, to the Russian 

Federation of services, software, 

hardware, or technology incident to the 

exchange of communications over the 

internet, such as instant messaging, 

videoconferencing, chat and email, 

social networking, sharing of photos, 

movies, and documents, web browsing, 

blogging, web hosting, and domain 

name registration services, that is 

prohibited by the RuHSR, is authorized. 

(c) This general license does not 

authorize: 

(1) The opening or maintaining of a 

correspondent account or payablethrough account for or on behalf of any 

entity subject to Directive 2 under 

Executive Order (E.O.) 14024, 

Prohibitions Related to Correspondent 

or Payable-Through Accounts and 

Processing of Transactions Involving 

Certain Foreign Financial Institutions; 

(2) Any debit to an account on the 

books of a U.S. financial institution of 

the Central Bank of the Russian 

Federation, the National Wealth Fund of 

the Russian Federation, or the Ministry 

of Finance of the Russian Federation; 

(3) Any transactions prohibited by 

E.O. 14066 or E.O. 14068; or 

(4) Any transactions involving Joint 

Stock Company Channel One Russia, 

Joint Stock Company NTV Broadcasting 

Company, or Television Station Russia1, unless separately authorized. 

(d) Effective May 8, 2022, General 

License No. 25, dated April 7, 2022, is 

replaced and superseded in its entirety 

by this General License No. 25A. 

Note to General License No. 25A. 

Nothing in this general license relieves 

any person from compliance with any 

other Federal laws or requirements of 

other Federal agencies, including 

export, reexport, and transfer (incountry) licensing requirements 

maintained by the Department of 

Commerce’s Bureau of Industry and 

Security under the Export 

Administration Regulations, 15 CFR 

parts 730–774. 

Andrea M. Gacki 

Director, Office of Foreign Assets Control 

Dated: May 8, 2022 


lotter on DSK11XQN23PROD with RULES1